Stephen Vincent, MD
Neurology · Idaho Falls, IDNPI 1932221306
Payments from drug & device makers
Across 594 payments — averaging $261.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$54K
- E.r. Squibb & Sons, L.L.C.$37K
- Sanofi$35K
- Bristol Myers Squibb$15K
- EMD Serono, Inc.$9K
- AbbVie$2K
- plus $4K from 32 others
Across 8 payments — averaging $263.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 69 | $54,023 |
| E.r. Squibb & Sons, L.L.C. | 42 | $37,079 |
| Sanofi | 73 | $34,591 |
| Bristol Myers Squibb | 104 | $15,203 |
| EMD Serono, Inc. | 51 | $8,862 |
| AbbVie(2 entities) | 107 | $1,886 |
| Biogen | 46 | $1,072 |
| Boston Scientific | 13 | $1,048 |
| Teva Pharmaceuticals USA, Inc. | 10 | $330 |
| Novartis | 25 | $298 |
| TG Therapeutics, Inc. | 5 | $118 |
| Acadia Pharmaceuticals Inc | 4 | $82 |
| Lilly USA, LLC | 3 | $62 |
| Acorda Therapeutics, Inc | 3 | $59 |
| Livanova USA, Inc. | 4 | $58 |
| Sunovion Pharmaceuticals Inc. | 3 | $58 |
| Neurocrine Biosciences, Inc. | 3 | $57 |
| Merz Pharmaceuticals, LLC | 2 | $56 |
| Neurelis, Inc. | 3 | $55 |
| Argenx US, Inc. | 3 | $54 |
| Lundbeck LLC | 2 | $53 |
| AstraZeneca | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $39 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| Harmony Biosciences LLC | 1 | $28 |
| SK Life Science, Inc. | 1 | $26 |
| Abbott | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Cala Health, Inc. | 1 | $23 |
| Irhythm Technologies, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 2 | $21 |
| Medtronic | 1 | $19 |
| CSL Behring | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
How this compares
$155,508 in reported general payments places this provider in the 90th percentile of 59 neurology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Idaho Falls
- Bradford TalcottIdaho Falls$252K
- Erich GarlandIdaho Falls$33K
- Shahzaib TariqIdaho Falls$647
- Nina BozinovCoeur D Alene$509K
- Lawrence GreenNampa$193K
- Angela PanaCoeur D Alene$37K
- Lukas ClarkBoise$37K
- Stephen AsherMeridian$35K
- Sergei KashirnyBoise$20K
- Richard HammondTwin Falls$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.